ESTRO 2025 - Abstract Book

S1498

Clinical – Mixed sites & palliation

ESTRO 2025

multivariate analysis, only radioresistant primary tumors (HR, 7.91; 95%, CI 1.79-35.03; 2-sided P =.01) were found to be prognostic for adverse overall survival. There were no grade ≥4 adverse events. The crude rate of grade 3 adverse events was less than 6%; no myelopathy or plexopathy were reported. Cumulative incidence of VCF was 1.6% and 4% at 1 and 2 years, respectively. No prognostic factors for VCF were identified on univariate analysis.